Search: onr:"swepub:oai:lup.lub.lu.se:7f05e264-f542-46e3-95d7-85ca970fb665" >
Non-pharmacological...
Non-pharmacological Effects in Switching Medication : The Nocebo Effect in Switching from Originator to Biosimilar Agent
-
- Kristensen, Lars Erik (author)
- Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,University of Copenhagen
-
- Alten, Rieke (author)
- Schlosspark-Klinik, Berlin
-
- Puig, Luis (author)
- Hospital de Sant Pau,Autonomous University of Barcelona
-
show more...
-
- Philipp, Sandra (author)
- Charité - University Medicine Berlin
-
- Kvien, Tore K. (author)
- Diakonhjemmet Hospital
-
- Mangues, Maria Antonia (author)
- Hospital de Sant Pau
-
- van den Hoogen, Frank (author)
- Radboud University Medical Center,Sint Maartenskliniek
-
- Pavelka, Karel (author)
- Institute of Rheumatology, Prague
-
- Vulto, Arnold G. (author)
- Erasmus University Medical Center,Catholic University of Leuven
-
show less...
-
(creator_code:org_t)
- 2018-09-29
- 2018
- English 8 s.
-
In: BioDrugs. - : Springer Science and Business Media LLC. - 1173-8804 .- 1179-190X. ; 32:5, s. 397-404
- Related links:
-
http://dx.doi.org/10... (free)
-
show more...
-
https://link.springe...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- The nocebo effect is defined as the incitement or the worsening of symptoms induced by any negative attitude from non-pharmacological therapeutic intervention, sham, or active therapies. When a patient anticipates a negative effect associated with an intervention, medication or change in medication, they may then experience either an increase in this effect or experience it de novo. Although less is known about the nocebo effect compared with the placebo effect, widespread interest in the nocebo effect observed with statin therapy and a literature review highlighting the nocebo effect across at least ten different disease areas strongly suggests this is a common phenomenon. This effect has also recently been shown to play a role when introducing a medication or changing an established medication, for example, when switching patients from a reference biologic to a biosimilar. Given the important role biosimilars play in providing cost-effective alternatives to reference biologics, increasing physician treatment options and patient access to effective biologic treatment, it is important that we understand this phenomenon and aim to reduce this effect when possible. In this paper, we propose three key strategies to help mitigate the nocebo effect in clinical practice when switching patients from reference biologic to biosimilar: positive framing, increasing patient and healthcare professionals’ understanding of biosimilars and utilising a managed switching programme.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Farmaceutiska vetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Pharmaceutical Sciences (hsv//eng)
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
-
BioDrugs
(Search for host publication in LIBRIS)
To the university's database